DECEMBER 20246Managing EditorAlex D'souzaVisualizerKevin ParkerDECEMBER - 2 - 2024, volume 07 - Issue 33 ISSN 2691-4093 Published by ValleyMedia, Inc. Emailsales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comTo subscribe to Medical Tech OutlookVisit www.medicaltechoutlook.com Copyright © 2024 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comThe regenerative medicine market is poised to transform healthcare in 2024, bringing hope for once-untreatable conditions through innovations that repair or replace damaged tissues and organs. The market is expanding rapidly, fueled by the rising prevalence of degenerative disorders and an intensified focus on novel regenerative therapies.Gene therapy is one of the most promising advancements in regenerative medicine, offering long-term solutions and potential cures for diseases like cancer and diabetes by correcting genetic disorders at the source. Similarly, stem cell technology is revolutionising treatment for conditions like knee osteoarthritis. With increasing research grants and off-the-shelf therapy developments, stem cells are bridging the gap between research and clinical application, widening the impact of regenerative medicine.Technological innovation is also reshaping the field. Research in extracellular vesicles (EVs) suggests they may enhance tissue regeneration as an alternative to stem cell therapies. The integration of artificial intelligence in drug development is expected to drive further market growth, with projections placing the global regenerative medicine market at $30.43 billion by 2030, growing at a CAGR of 16.79 percent.This edition of MedTech Outlook Europe, offers critical insights into the evolving medical device landscape through a thought leadership piece by Stefanie Hirsch, Chief Sustainability & Quality Officer, Member of the Executive Board at Drägerwerk AG & Co. KGaA. Hirsch explores Dräger's harmonised, adaptable quality management system and proactive approach to regulatory compliance, highlighting the critical need for robust cybersecurity, hygienic processing, and biocompatibility standards in today's complex regulatory environment.Also featured is an article by Sophie Morales, Head of service at CEA-Leti, discussing innovations in cell-culture monitoring through lens-free microscopy. Morales showcases how this technology facilitates real-time, label-free cell analysis and opens new avenues in drug screening and bio-production monitoring by overcoming challenges in dense cell imaging.In this edition featuring the Top Regenerative Medicine Solutions Providers in Europe 2024, we hope you find the right partner to meet your organisation's needs. Let us know your thoughts!EDITORIALEditorial StaffJoe PhilipLaura PintoJoshua ParkerMerlin WatsonSarah FernandesGina ClumskyYenny TurnerTiffany HayworthNext-Gen Regenerative Medicine Set to Revolutionise Healthcare
< Page 5 | Page 7 >